Swiss National Bank Purchases 100,900 Shares of Pfizer Inc. (NYSE:PFE)

Swiss National Bank increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 0.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,819,712 shares of the biopharmaceutical company's stock after purchasing an additional 100,900 shares during the period. Swiss National Bank owned approximately 0.30% of Pfizer worth $486,762,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Pfizer in the first quarter worth approximately $315,000. Jupiter Asset Management Ltd. bought a new stake in shares of Pfizer during the 1st quarter valued at $3,221,000. Edgestream Partners L.P. bought a new stake in shares of Pfizer during the 1st quarter valued at $243,000. Hillsdale Investment Management Inc. increased its stake in shares of Pfizer by 111.3% in the 1st quarter. Hillsdale Investment Management Inc. now owns 3,132 shares of the biopharmaceutical company's stock worth $87,000 after purchasing an additional 1,650 shares in the last quarter. Finally, Resurgent Financial Advisors LLC raised its holdings in Pfizer by 16.6% in the 1st quarter. Resurgent Financial Advisors LLC now owns 36,270 shares of the biopharmaceutical company's stock worth $1,007,000 after purchasing an additional 5,173 shares during the period. Institutional investors own 68.36% of the company's stock.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.06% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on PFE. StockNews.com upgraded Pfizer from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, November 12th. UBS Group raised their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 31st. Barclays increased their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a "neutral" rating to an "outperform" rating and raised their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $32.92.

Pfizer Price Performance

Shares of PFE stock traded down $1.22 during trading hours on Friday, hitting $24.80. The stock had a trading volume of 131,074,383 shares, compared to its average volume of 44,243,800. The stock's 50-day moving average price is $28.64 and its two-hundred day moving average price is $28.67. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a market capitalization of $140.54 billion, a price-to-earnings ratio of 33.51, a PEG ratio of 0.79 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company's revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.17) EPS. Equities analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.77%. Pfizer's payout ratio is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.